The 2024 Myeloma Landscape with Robert Orlowski, MD, PhD, MD Anderson
Myeloma Crowd Radio
by HealthTree Podcast for MM
5M ago
The year 2024 brings new promise in multiple myeloma with a wide variety of treatment options avaiable for both newly diagnosed and relapsed/refractory patients. Learn about the progress being made and the very latest in determining risk at diagnosis, strategies for smoldering myeloma patients, optimal treatments for newly diagnosed patients, things to consider at first relapse and beyond. Dr. Robert Orlowski will review advances in CAR T therapies, bispecific antibodies, targeted therapies and combination approaches and clinical trials to watch as the research continues advancing at a rapid p ..read more
Visit website
Today's CAR T Options in Multiple Myeloma Care with Luciano Costa, MD, UAB
Myeloma Crowd Radio
by HealthTree Podcast for MM
8M ago
CAR T therapy is a highly effective treatment for myeloma patients, even in highly relapsed multiple myeloma. In today's show we will hear from Luciano Costa, MD of the University of Burmingham who will do a deep dive into CAR T therapy in multiple myeloma to discuss how CAR T availability is improving, how CAR T is being tested in earlier lines of therapy, side effects to consider, new CAR T targets, combo CAR Ts, maintenance therapy post-CAR T, open CAR T clinical trials and various new forms CAR T variants like NK CAR Ts. Join us for this important show on one of the most impressive therapi ..read more
Visit website
Multiple myeloma mid-year progress with Dr. Paul Richardson of Dana Farber
Myeloma Crowd Radio
by HealthTree Podcast for MM
9M ago
Dr. Paul Richardson of the Dana Farber Cancer Institute shares a mid-year myeloma review of ASCO, EHA and upcoming International Myeloma Society findings of the fast-moving research being performed in myeloma. Updates will include the expanding world of bispecific antibodies that include one FDA-approved drug and anticipated approvals for two new bispecific antibodies. He will also discuss exciting results from CAR T cinical trials,  CAR T newcomers, sequencing preferences, BCMA targeted therapies, new therapy targets in myeloma, MRD advances, blood-based testing, clinical trials end poin ..read more
Visit website
Stem Cell Transplant Advances and Use in the Age of Immunotherapy
Myeloma Crowd Radio
by HealthTree Podcast for MM
9M ago
Stem cell transplant remains a useful and widely used treatment for multiple myeloma. John DiPersio, MD, PhD of the Siteman Cancer Center at Washington University joins HealthTree Podcast for Multiple Myeloma to discuss stem cell transplant in myeloma, a new and better way to collect stem cells as part of the process and the utility of stem cell transplant in the age of immunotherapies.  Thanks to our episode sponsor, GSK ..read more
Visit website
Essential Research for Myeloma Cures with Faith Davies, NYU
Myeloma Crowd Radio
by HealthTree Podcast for MM
10M ago
The cure for multiple myeloma only happens with patient participation in research. In this episode, Faith Davies, MBBCh, MRCP, MD, FRCPath of the NYU Langone will share how research works in multiple myeloma, the various stages in clinical trials, the most critical steps that move curative therapies forward, how barriers to a cure can be removed and how patient participation is essential to the entire process.  Thanks to our episode sponsor, GSK ..read more
Visit website
The Utility of MRD Testing for Myeloma Patient Treatment and Outcomes
Myeloma Crowd Radio
by HealthTree Podcast for MM
1y ago
Minimal Residual Disease (MRD) testing is a more sensitive way to test for remaining disease following myeloma treatment. Its use could change the way experts treat multiple myeloma now and in the future. MRD testing may help determine which patients should stay on treament or which patients are able to stop if they stay MRD negative for a long period of time. It may help prevent over or under treating patients.  In this show Benjamin Derman, MD of the University of Chicago shares what MRD testing is, how it's being used in clinical trials as a new clinical trial end point, what the FDA w ..read more
Visit website
Understanding Blood-Based Testing in Multiple Myeloma with Ola Landgren, MD, PhD
Myeloma Crowd Radio
by HealthTree Podcast for MM
1y ago
A wave of blood-based tests are being researched for myeloma care, and for good reason. Patients love the idea of replacing the painful bone marrow biopsy with a blood-based test, especially if it is equally effective. In addition to being less time consuming and painful, blood-based testing could be performed more regularly to provide more information to patients and their doctors.  The types of test vary. They include mass spectometry testing, blood-based MRD testing and circulating tumor cell testing. Many of these tools are still only used in research, but they are getting closer ..read more
Visit website
HealthTree Podcast for Myeloma: Ashraf Badros, MD, University of Maryland
Myeloma Crowd Radio
by HealthTree Podcast for MM
1y ago
Maintenance therapy over the past several years has commonly included the use of Revlimid (lenalidomide) over a long period of time. Is more better? Does more maintenance therapy or certain combinations help extend remissions or help patients deepen their responses?  Ashraf Badros, MD, of the University of Maryland will join the HealthTree Podcast for Multiple Myeloma to talk with us about the rationale behind the AURIGA clinical trial using daratumumab and lenalidomide following stem cell transplant for patients who are still MRD positive.  Myeloma experts are working to identify mo ..read more
Visit website
HealthTree Podcast for Multiple Myeloma: Dr. Robert Orlowski on Myeloma in 2022
Myeloma Crowd Radio
by HealthTree Podcast for MM
1y ago
Dr. Robert Z. Orlowski joins Myeloma Crowd Radio to share a study to share the new innovations myeloma patients can expect in 2022. He will review the recent findings from the American Society of Hematology meeting and share what we can expect from new combination therapies, best options for newly diagnosed myeloma patients, expected FDA approvals in 2022, CAR T advances, bispecific and trispecific antibodies, antibody drug conjugates, targeted inhibitors and new approaches for MGUS and smoldering myeloma. We invite you to join us for this well loved annual show.  Dr. Orlowski i ..read more
Visit website
HealthTree Podcast for Myeloma: Shaji Kumar, MD, Mayo Clinic on ETBs in Myeloma
Myeloma Crowd Radio
by HealthTree Podcast for MM
1y ago
A new approach in myeloma immunotherapies is in the works called Engineered Toxic Bodies (ETBs). Early on, Molecular Templates partnered with Takeda Oncology to begin development on an ETB therapy for multiple myeloma targeting CD38. Currently, Molecular Templates is moving this therapy forward. ETBs work differently from monoclonal antibodies because they move deep inside the plasma cell instead of flagging the cell's surface. They also don't rely on the body's own immune system (like T cells or NK cells) to kill myeloma. Learn more about this emerging therapy from Dr. Shaji Kumar on thi ..read more
Visit website

Follow Myeloma Crowd Radio on FeedSpot

Continue with Google
Continue with Apple
OR